Swami Laboratories Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 09-12-2024
- Paid Up Capital ₹ 2.00 M
as on 09-12-2024
- Company Age 31 Year, 7 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.62 Cr
as on 09-12-2024
- Satisfied Charges ₹ 1.35 Cr
as on 09-12-2024
- Revenue -35.94%
(FY 2020)
- Profit 114.49%
(FY 2020)
- Ebitda 41.68%
(FY 2020)
- Net Worth 1.65%
(FY 2020)
- Total Assets 1.73%
(FY 2020)
About Swami Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹1.62 Cr. The company has closed loans amounting to ₹1.35 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vijay Bajja, Sanyog Bajaj, Paras Bajaj, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232DL1993PTC053493
- Company No.
053493
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 May 1993
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Swami Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Bajja  | Director | 11-May-1993 | Current |
| Sanyog Bajaj | Director | 12-Apr-2017 | Current |
| Paras Bajaj | Director | 12-Apr-2017 | Current |
| Kanchan Bajaj | Director | 17-Sep-2020 | Current |
Financial Performance of Swami Laboratories.
Swami Laboratories Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 35.94% decrease. The company also saw a substantial improvement in profitability, with a 114.49% increase in profit. The company's net worth moved up by a moderate rise of 1.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Swami Laboratories?
In 2019, Swami Laboratories had a promoter holding of 80.02% and a public holding of 19.98%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Tarqeebein Media And Entertainment Private LimitedActive 12 years 8 months
Paras Bajaj is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Centurion Bank Of Punjab Limited Creation Date: 28 Jun 2007 | ₹2.51 M | Open |
Centurion Bank Of Punjab Limited Creation Date: 28 Jun 2007 | ₹1.37 Cr | Open |
Icici Bank Branch Creation Date: 22 Oct 2006 | ₹5.00 M | Satisfied |
How Many Employees Work at Swami Laboratories?
Unlock and access historical data on people associated with Swami Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Swami Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Swami Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
